Summary
Danaher Corporation reported mixed results for the second quarter of 2025. Overall revenues saw a modest increase of 3.5% year-over-year, driven by a 2.0% contribution from currency exchange rates and 1.5% from core sales. However, net earnings and diluted earnings per share experienced a significant decline compared to the prior year, primarily due to a substantial impairment charge of $432 million related to a trade name in the Life Sciences segment. While the Biotechnology segment showed robust growth with an 8.0% increase in total sales (6.0% core sales growth), the Life Sciences segment experienced a 2.5% decline in core sales, and the Diagnostics segment saw flat core sales growth for the six-month period. Operating profit margins were negatively impacted by the aforementioned impairment charge and the dilutive effect of recent acquisitions. Despite these challenges, Danaher's liquidity remains strong, with $3.0 billion in cash and cash equivalents. The company continues to generate significant operating cash flow, though it decreased by 16% year-over-year for the first six months of 2025, largely due to lower net earnings and increased non-cash charges. The company is actively managing its capital structure, with a reduced pace of share repurchases in the current period compared to the previous year and an increase in dividend payments.
Financial Highlights
51 data points| Revenue | $5.94B |
| Cost of Revenue | $2.41B |
| Gross Profit | $3.52B |
| R&D Expenses | $403.00M |
| SG&A Expenses | $2.36B |
| Operating Income | $760.00M |
| Net Income | $555.00M |
| EPS (Basic) | $0.77 |
| EPS (Diluted) | $0.77 |
| Shares Outstanding (Basic) | 716.50M |
| Shares Outstanding (Diluted) | 719.10M |
Key Highlights
- 1Overall revenue increased by 3.5% year-over-year, with core sales growing by 1.5% in Q2 2025.
- 2Net earnings and diluted EPS declined significantly due to a $432 million impairment charge in the Life Sciences segment.
- 3The Biotechnology segment demonstrated strong performance with an 8.0% total sales growth (6.0% core sales growth) in Q2 2025.
- 4The Life Sciences segment reported a 2.5% core sales decline in Q2 2025, impacted by lower demand in genomics consumables and protein product lines.
- 5Operating profit margins decreased substantially, heavily influenced by impairment charges and the dilutive impact of acquisitions.
- 6The company maintains a strong liquidity position with $3.0 billion in cash and cash equivalents as of June 27, 2025.
- 7Operating cash flow decreased by 16% for the first six months of 2025 compared to the prior year.